津药药业股份有限公司 2023 年年度股东大会 津药药业股份有限公司 2023 年年度股东大会 会议资料 2024 年 4 月 1 / 46 津药药业股份有限公司 2023 年年度股东大会 目录 | 议案一：2023 | 年度董事会工作报告 | 3 | | --- | --- | --- | | 议案二：2023 | 年度监事会工作报告 | 8 | | 议案三：2023 | 年度财务决算草案 | 13 | | 议案四：2023 | 年度利润分配预案 | 15 | | 议案五：2023 | 年年度报告及其摘要 | 16 | | 议案六：关于续聘会计师事务所的议案 | | 17 | | 报告事项：2023 | 年度独立董事述职报告 | 20 | 2 / 46 津药药业股份有限公司 2023 年年度股东大会 津药药业 2023 年年度股东大会会议议案之一 （三）认真履行董事会工作职责，确保董事会股东大会依法合规 运作 3 / 46 2023 年公司共召开董事会 10 次、股东大会 3 次，董事参加董事 2023 年度董事会工作报告 (已经 2024 年 3 月 27 日第九届董事会第 6 次会议审议通过) 一、20 ...

Financial Performance - In 2023, the company achieved operating revenue of CNY 3.78 billion, a 2.55% increase compared to CNY 3.69 billion in 2022[14]. - The net profit attributable to shareholders reached CNY 117.05 million, representing a significant increase of 230.60% from CNY 35.41 million in the previous year[14]. - The net cash flow from operating activities was CNY 783.01 million, up 19.81% from CNY 653.52 million in 2022[14]. - The weighted average return on net assets increased to 3.95%, up 2.76 percentage points from 1.19% in 2022[14]. - Basic and diluted earnings per share were both CNY 0.107, a remarkable increase of 234.38% compared to CNY 0.032 in 2022[14]. - The total assets decreased by 7.64% to CNY 6.14 billion from CNY 6.65 billion in 2022[14]. - The company reported a revenue of CNY 2.08 billion from steroid hormones and CNY 366 million from amino acids in its main business[22]. Dividend Distribution - The company plans to distribute a cash dividend of 0.87 RMB per 10 shares, totaling 95,172,143.16 RMB, resulting in a cash dividend payout ratio of 81.31%[4]. - The company reported a total distributable profit of 919,864,134.95 RMB as of December 31, 2023[4]. Product Development and Market Position - The company has accelerated product registration and increased sales regions and customer numbers, particularly focusing on the successful bids for six products in the national drug procurement[12]. - The company has developed a total of 17 dosage forms, including injections, ointments, and tablets, with a strong emphasis on quality management and compliance with GMP standards[8]. - The company has achieved domestic firsts in consistency evaluation for several products, enhancing its market competitiveness and brand recognition[12]. - The company operates two major industrial bases in Tianjin, focusing on the R&D, production, and sales of steroid hormones and amino acid raw materials[8]. Supply Chain and Relationships - The company has established stable and friendly relationships with qualified suppliers through years of supply chain management[10]. - The company has over 60% of its steroid hormone raw materials exported to more than 70 countries and regions across Asia, Europe, and America, with domestic sales covering nearly 100 cities[9]. Recognition and Management Practices - The company is recognized as a national high-tech enterprise and has received multiple honors, including being a leading technology enterprise in Tianjin[9]. - The company emphasizes lean management to reduce waste and improve production efficiency, ensuring better market responsiveness[12]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,376, a slight decrease from 43,611 in the previous month[18]. - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., held 50.69% of the shares, totaling 554,530,149 shares[18]. Export Performance - The company exported goods worth USD 13.24 million during the reporting period[22].

Financial Performance - The company achieved operating revenue of RMB 3.78 billion in 2023, a 2.55% increase compared to RMB 3.69 billion in 2022[23]. - Net profit attributable to shareholders reached RMB 117.05 million, marking a significant increase of 230.60% from RMB 35.41 million in the previous year[23]. - Basic and diluted earnings per share rose to RMB 0.107, reflecting a growth of 234.38% compared to RMB 0.032 in 2022[24]. - The net cash flow from operating activities improved by 19.81%, totaling RMB 783.01 million, up from RMB 653.52 million in 2022[23]. - The company reported a decrease in total assets by 7.64%, down to RMB 6.14 billion from RMB 6.65 billion at the end of 2022[23]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 15% year-over-year growth[164]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[166]. Dividend and Shareholder Returns - The company's distributable profit as of December 31, 2023, is CNY 919,864,134.95, with a proposed cash dividend of CNY 0.87 per 10 shares, totaling CNY 95,172,143.16, resulting in a cash dividend payout ratio of 81.31%[4]. - The total cash dividend amount (including tax) is 95,172,143.16 CNY, which accounts for 81.31% of the net profit attributable to ordinary shareholders in the consolidated financial statements[193]. - The net profit attributable to ordinary shareholders in the consolidated financial statements is 117,052,520.50 CNY[193]. Research and Development - Total R&D investment reached 194.83 million yuan, which is 5.15% of the operating revenue[60]. - The number of R&D personnel is 492, accounting for 18% of the total workforce[61]. - The company is committed to enhancing its research and development efforts to introduce innovative products in the pharmaceutical market[86]. - The company is focusing on expanding its product offerings in the pharmaceutical sector, with several drugs in various stages of development and approval[95]. - The company has multiple products in the consistency evaluation stage, indicating a strong pipeline for future approvals[95]. - The company has received approval for multiple raw materials and drug products, including "曲伏前列素" for lowering intraocular pressure in glaucoma patients[98]. Market Position and Strategy - The company has established a solid market position in the domestic market, leveraging its technical advantages and extensive experience[72]. - The company aims to actively expand its overseas business through international exhibitions, technical cooperation, and market promotion[72]. - The company is strategically positioning itself for future growth by adapting to regulatory changes and expanding its product offerings in response to market trends[83]. - The company has accelerated its global expansion, currently holding 17 CEP certificates and 23 products certified by the US DMF, indicating a strong international market presence[32]. - The company is focusing on expanding its product offerings in the oncology segment, particularly with Fluorouracil Injection for treating various cancers[86]. Operational Efficiency - The company emphasized cost reduction and efficiency improvement, contributing to enhanced operational performance[31]. - The company achieved significant improvements in production efficiency through lean management, focusing on five key areas: scientific scheduling, energy consumption reduction, cost control, quality assurance, and labor productivity enhancement[32]. - The company has implemented multiple technical improvements, resulting in a decrease in production costs and an increase in product quality[44]. - The company has established stable partnerships with qualified suppliers through years of supply chain management, optimizing procurement processes to reduce management costs[39]. Compliance and Governance - The company has received a standard unqualified audit report from Zhongshun Hua Accounting Firm[7]. - The company has confirmed that all board members attended the board meeting, ensuring the authenticity and completeness of the annual report[7]. - The company has not reported any other significant issues or changes outside of the management restructuring[170]. - The company has conducted three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[158]. - The company has updated its internal governance documents to align with the latest regulatory requirements, improving decision-making efficiency[154]. Environmental and Safety Management - The company actively responds to national and local environmental protection policies, enhancing its environmental management practices in line with new regulations implemented in 2023[83]. - New safety production regulations emphasize corporate responsibility and increased government oversight, prompting the company to improve its safety management systems and invest in automation and safety upgrades[80]. - The company has implemented automation upgrades across multiple production facilities to enhance safety and reduce risks associated with potential accidents[151]. Human Resources and Compensation - The company has established a differentiated salary system and performance evaluation mechanism to enhance employee motivation[186]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 7.5761 million yuan[168]. - The company has implemented a performance-related compensation mechanism for its management team, linking their remuneration to corporate performance and individual achievements[196]. - The company has a training plan aimed at improving employee skills and capabilities to support rapid business growth[187]. Challenges and Risks - The company faces risks related to raw material price increases and supply shortages, which it plans to mitigate through strategic procurement and inventory management[144]. - Environmental regulations pose a risk to the company's operations, necessitating increased investment in compliance and sustainable practices[148]. - The company acknowledges the risks associated with policy changes and aims to enhance its R&D quality and speed to adapt to market demands[147].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600488 证券简称：津药药业 编号：2024-014 津药药业股份有限公司 关于续聘会计师事务所的公告 重要内容提示： 拟聘任的会计师事务所名称：中审华会计师事务所（特殊普通 合伙） 原聘任的会计师事务所名称：中审华会计师事务所（特殊普通 合伙） 津药药业股份有限公司（以下简称"公司"）于2024年3月27日召 开公司第九届董事会第六次会议，审议通过了《关于续聘会计师事务 所的议案》，拟续聘中审华会计师事务所（特殊普通合伙）（以下简 称"中审华"）为公司2024年度财务审计和内控审计机构。具体情况如 下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 会计师事务所名称：中审华会计师事务所（特殊普通合伙） 成立日期：2000 年 9 月 19 日 组织形式：特殊普通合伙 注册地址：天津 首席合伙人：黄庆林 上年度末合伙人数量：103 人 上年度末注册会计师人数：516 人 上年度末签署过证券服务业务审计报告的注册会计师人数：114 人 最近一年 ...

津药药业股份有限公司 2023 年度社会责任报告 本公司董事会及全体董事保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 董事长致辞 Chairman's Speech 冬雪消融新春至，万象更新显生机。2023 年，对于我们来说，是充满挑战与机遇的一年。全体员工 团结奋进、务实求变，以创新为引擎，以质量为基石，以客户需求为导向，开创了事业发展新局面。这一年， 我们创造的利润实现大幅增长，组织变革取得突破，药品研发更是硕果累累。 我们始终坚守制药人的初心，严守药品质量关，致力于研发安全、有效、高品质的医药产品，满足广 大患者的需求，助力提升国民健康水平。同时，我们积极响应国家政策导向，积极参与医药行业的深化改革， 优化资源配置，提升运营效率，力求实现经济效益与社会效益的双丰收。 我们高度重视员工权益与发展，努力构建和谐劳动关系，提供安全的工作环境和良好的职业发展空间， 鼓励员工在专业领域内持续精进，并积极参与各类社会公益行动，共同塑造有温度、有担当的企业文化。 2023 年已经成为历史，但其所承载的奋斗与成就将激励我们在 2024 年开启新的征程。 ...

证券代码：600488 证券简称：津药药业 编号：2024-016 津药药业股份有限公司 第九届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届监事会第四次会 议于 2024 年 3 月 27 日以现场和通讯表决相结合的方式召开。会议由监 事会主席赵炜先生主持，应参加表决监事 3 人，实际表决监事 3 人。会 议符合《中华人民共和国公司法》和《公司章程》的有关规定。会议经 过审议，与会监事全票通过如下提案： 1. 审议通过《2023 年度总经理工作报告》 表决结果：同意【3】票，反对【0】票，弃权【0】票。 2. 审议通过《2023 年度监事会工作报告》 表决结果：同意【3】票，反对【0】票，弃权【0】票。此项议案需 提交公司 2023 年年度股东大会审议。 3. 审议通过《2023 年度财务决算草案》 表决结果：同意【3】票，反对【0】票，弃权【0】票。此项议案需 提交公司 2023 年年度股东大会审议。 4. 审议通过《2023 年度利润分配预案 ...

（一）独立董事变动情况 公司第八届董事会任期于 2023 年 11 月 12 日届满，为进一步完 善公司治理结构，保障公司有效决策、维护公司稳定有序的经营环境， 公司董事会提前换届选举，我被提名为公司第九届董事会的独立董事 候选人。2023 年 9 月 22 日，经公司 2023 第二次临时股东大会审议 通过，同意选举我为公司第九届董事会独立董事。 津药药业股份有限公司 2023 年度独立董事述职报告 我作为津药药业股份有限公司（以下简称"公司"）的独立董事， 根据《公司法》《证券法》《上市公司独立董事管理办法》《公司章 程》及《独立董事工作制度》等规定和要求，在2023年度工作中，认 真履行职责，积极出席相关会议，认真审议董事会各项议案，对重大 事项发表了独立意见，维护了公司整体利益及全体股东的合法权益。 现将2023年度履行职责情况述职如下： 一、独立董事的基本情况 （二）工作履历、专业背景以及兼职情况 我作为财务与会计领域的专业人士，符合国家相关法律法规中关 于上市公司独立董事人数专业配置的要求，主要工作履历、专业背景 及兼职情况如下： 边泓，男，1969年生人，南开大学会计专业博士。现任公司独立 董事 ...

证券代码：600488 证券简称：津药药业 编号：2024-010 津药药业股份有限公司 第九届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第六次会 议于 2024 年 3 月 27 日以现场和通讯表决相结合的方式召开。本次会议 的通知已于 2024 年 3 月 17 日以电子邮件的方式送达公司各位董事、监 事和高管人员。会议应参加表决董事 9 人，实际表决董事 9 人，公司监 事及部分高管人员列席了会议。会议符合《中华人民共和国公司法》和 《公司章程》的有关规定，决议如下： 1.审议通过《2023 年度总经理工作报告》 表决结果：同意【9】票，反对【0】票，弃权【0】票。 2.审议通过《2023 年度董事会工作报告》 表决结果：同意【9】票，反对【0】票，弃权【0】票。本议案需提 交公司 2023 年年度股东大会审议。 3.审议通过《2023 年度财务决算草案》 表决结果：同意【9】票，反对【0】票，弃权【0】票。本议案需提 交公司 20 ...

关于津药药业股份有限公司 控股股东及其他关联方 资金占用情况的专项说明 CAC 证专字[2024]0083 号 中审华会计师事务所 (特殊普通合伙) 在线上海作用 骑维 关于津药药业股份有限公司 控股股东及其他关联方资金占用情况的专 项说明 CAC证专字[2024]0083号 津药药业股份有限公司全体股东: 我们审计了津药药业股份有限公司(以下简称"津药药业")2023年 12 月 31 日合并及母公司资产负债表、2023年度的合并及母公司利润表、现金流 量表、股东权益变动表以及财务报表附注(以下简称"财务报表"),并出具了 报告号为 CAC 证审字[2024]0013 号的无保留意见审计报告。财务报表的编制和 公允列报是津药药业管理层的责任,我们的责任是在按照中国注册会计师审计 准则执行审计工作的基础上对财务报表整体发表审计意见。 根据中国证券监督管理委员会、中华人民共和国公安部、国务院国有资产监 督管理委员会、中国银行保险监督管理委员会《上市公司监管指引第 8 号 -- 上 市公司资金往来、对外担保的监管要求》(中国证券监督管理委员会公告(2022) 26 号)的要求,津药药业编制了后附的 2023年度非 ...